[Rituximab Based Treatment in Pediatric Epsstain Bar Virus Associated Lymphocyte Proliferative Diseases After Aplastic Anemia with Haplo-identical Transplantation:a Prospective Single Centre Study]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2024 Sep 4

PMID 39231773

Authors

F Zhang

G H Hu

P Suo

Z L Xu

L Bai

H F Wang

S Y M Huang

L P Xu

Y J Chang

X H Zhang

X J Huang

Y F Cheng

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) are one of the most severe complications after hematopoietic stem cell transplantation (HSCT). This study includes 31 cases of aplastic anemia (AA) patients who developed PTLD after haploidentical transplantation, summarizing their clinical characteristics and categorizing them into either rituximab monotherapy group or combination therapy group based on whether their condition improved by 1 log after a single dose of rituximab. The incidence of PTLD after HSCT in children with AA was 10.16%, and the incidence of PTLD in patients with age >10 years was significantly increased ((2)=11.336, =0.010). Of the 31 patients, 27 were clinically diagnosed and 4 were pathologically confirmed. Finally, 15 patients were classified into the rituximab treatment group and 15 patients into the combination treatment groups. Finally three patients died, and the 2-year overall survival rate was (89.7±5.6) %. Standard pre-treatment protocols and EBV reactivation are risk factors affecting the prognosis of PTLD. There was no statistically significant difference in the impact of the two treatment schemes on prognosis.

References

Kinch A, Hallbook H, Arvidson J, Sallstrom K, Bondeson K, Pauksens K . Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. Leuk Lymphoma. 2017; 59(5):1172-1179. DOI: 10.1080/10428194.2017.1365860. View

Zhu C, Zhao S, Wang X, Wang L, Wang F, Fang S . Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience. Ann Transplant. 2019; 24:175-184. PMC: 6463616. DOI: 10.12659/AOT.914101. View

Gao X, Lin J, Wang L, Li F, Li H, Wang S . Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Ann Hematol. 2019; 98(9):2163-2177. DOI: 10.1007/s00277-019-03742-7. View

Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T . Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(7):1441-1449. DOI: 10.1016/j.bbmt.2019.02.016. View

Xu L, Zhang C, Mo X, Zhang X, Chen H, Han W . Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biol Blood Marrow Transplant. 2015; 21(12):2185-2191. DOI: 10.1016/j.bbmt.2015.07.035. View

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

Styczynski J, van der Velden W, Fox C, Engelhard D, de la Camara R, Cordonnier C . Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7):803-11. PMC: 5004459. DOI: 10.3324/haematol.2016.144428. View

Yan H, Zheng X, Zhu L, Ding L, Han D, Liu J . [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022; 30(4):1224-1229. DOI: 10.19746/j.cnki.issn.1009-2137.2022.04.040. View

. [Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022)]. Zhonghua Xue Ye Xue Za Zhi. 2023; 43(9):716-725. PMC: 9613495. DOI: 10.3760/cma.j.issn.0253-2727.2022.09.002. View

10.

Garcia-Cadenas I, Yanez L, Jarque I, Martino R, Perez-Simon J, Valcarcel D . Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019; 102(6):465-471. DOI: 10.1111/ejh.13226. View

11.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

12.

Lin F, Zhang Y, Han T, Cheng Y, Mo X, Wang J . A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. Clin Transplant. 2021; 36(1):e14514. DOI: 10.1111/ctr.14514. View

13.

Lindsay J, Yong M, Greenwood M, Kong D, Chen S, Rawlinson W . Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Rev Med Virol. 2020; 30(4):e2108. DOI: 10.1002/rmv.2108. View

14.

Kim B, Kang H, Hong K, An H, Yoon Choi J, Lee J . Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Transpl Infect Dis. 2019; 21(6):e13182. DOI: 10.1111/tid.13182. View

15.

Liu D, Huang X, Liu K, Xu L, Chen H, Han W . Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant. 2008; 14(4):469-77. DOI: 10.1016/j.bbmt.2008.02.007. View